What the April 2026 503A Category Changes Mean for Prescribers

Current status, updated October 3, 2026. This article explains FDA’s April 15, 2026 update. Since then:

• In July 2026, PCAC voted to recommend adding six of these peptides to the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It voted against Emideltide (DSIP). See PCAC recommended six peptides. FDA has not added them.
• FDA has not added any of them to the final 503A bulks list in 21 CFR 216.23.
• None of the 12 substances has returned to Category 2. On May 14, 2026, FDA put GHK-Cu for non-injectable routes back in Category 1 after one nominator clarified that it had meant to withdraw only the injectable nomination.
• FDA continues to publish safety concerns about these substances.

Original April 2026 analysis

The sections below describe the April 15, 2026 update as it stood when this page was published on April 19, 2026. Wording has been clarified; the facts are as of that date.

The April 15, 2026 FDA update changed how several peptides were categorized, but it did not erase the difference between three separate things: removal from Category 2, a nomination for the 503A bulks list, and actual inclusion on that list.

What changed on April 15, 2026

• FDA updated its 503A categories document and gave notice that 12 peptide-related substances would be removed from Category 2 after seven calendar days.
• The reason was that the nominators had withdrawn their nominations. Category 2 is a group of nominated substances; when the nominations were withdrawn, FDA stopped listing those substances there. FDA did not say its safety concerns had been resolved.
• FDA separately announced a July 23–24, 2026 PCAC meeting to discuss seven of these substances for possible inclusion on the 503A bulks list.

What the April update did not mean

Removal from Category 2 was not FDA approval. It was not inclusion on the final 503A bulks list, and it did not move the substances into Category 1. It also did not remove the need for clinician, legal, and pharmacy review.

What clinicians should do

1. Use exact dates when discussing regulatory status with patients, staff, and pharmacy partners.
2. Do not shorten “removed from Category 2 after the nominations were withdrawn” to “FDA-approved” or “cleared for compounding.”
3. Check current FDA sources before relying on any April 2026 summary, including this one. See the current-status update at the top of this page.

Primary sources

For category status, use FDA’s 503A categories document, now updated May 14, 2026. For the July meeting agenda, use the Federal Register notice. For the final list, use 21 CFR 216.23 on eCFR.